ライフサイエンスコーパス: methylglutaryl

1 Use of 3-hydroxyl-3-methylglutaryl-3 coenzyme A reductase (HMGCR) inhibitors

2 rom clinical trials suggest that 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors may help

3 nism for this putative effect of 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors, and whe

4 ed by compactin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase that inhibits cho

5 c reticulum (ER)-resident enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the rat

6 Statins are inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase used for the ther

7 Inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, also known as st

8 bolic pathway by the hydrophobic 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase inhibitors, simvas

9 ate degradation of the ER enzyme 3-hydroxy-3-methylglutaryl CoA reductase (HMG CoA reductase), which

10 olesterol synthesis pathway with 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase) inhibit

11 MAD3 encodes 3-hydroxy-3-methylglutaryl CoA reductase (HMG1), which functions in

12 g fatty acid synthase (FASN) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR).

13 The enzymes 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) and C24-sterol methy

14 ars to control the expression of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) and l-phenylalanine

15 -2 (COX-2) inhibitors and statins [hydroxy-3-methylglutaryl CoA reductase (HMGR) inhibitors] inhibit

16 Inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (statins) reduce signs of d

17 ng the mevalonate (MVA) pathway, 3-Hydroxy-3-Methylglutaryl CoA Reductase 1 (HMGR1), interacts with D

18 reticulum (ER)-localized enzyme 3-hydroxy-3-methylglutaryl CoA reductase catalyzes a rate-limiting s

19 enase-2 inhibitor), and statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) inhibit colon c

20 The statins, 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, have pleiotropi

21 t (or longer) treatment with the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, the statins.

22 abolic product of the acetyl CoA/3-hydroxy-3-methylglutaryl CoA reductase reaction.

23 y-3-methylglutaryl CoA synthase, 3-hydroxy-3-methylglutaryl CoA reductase), and fatty acid synthase.

24 nd pravastatin are inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase, and are used as antihyperc

25 acid, a downstream metabolite of 3-hydroxy-3-methylglutaryl CoA reductase, confirming that simvastati

26 t selectively inhibit the enzyme 3-hydroxy-3-methylglutaryl CoA reductase, leading to decreased chole

27 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme o

28 cholesterol biosynthetic enzyme 3-hydroxy-3-methylglutaryl CoA reductase, thus inducing the ubiquiti

29 sterol-stimulated degradation of 3-hydroxy-3-methylglutaryl CoA reductase.

30 cholesterol biosynthetic enzyme 3-hydroxy-3-methylglutaryl CoA reductase.

31 3-Hydroxy-3-methylglutaryl CoA synthase (HMGS) catalyzes the first c

32 Haloferax 3-hydroxy-3-methylglutaryl CoA synthase is sensitive to inactivation

33 uired for cholesterol synthesis (3-hydroxy-3-methylglutaryl CoA synthase, 3-hydroxy-3-methylglutaryl

34 tyl-CoA and acetoacetyl-CoA into 3-hydroxy-3-methylglutaryl CoA.

35 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase catalyzes the divalen

36 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase is a key enzyme in th

37 PC1L1) inhibitor (ezetimibe) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (stati

38 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or st

39 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limit

40 ays between the OleA homologues, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase and the fatty acid

41 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase catalyzes the firs

42 after they decrease the level of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA).

43 RAF V600E and a ketogenic enzyme 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL).

44 s expression of ketogenic enzyme 3-hydroxy-3-methylglutaryl-CoA lyase and promotes the formation of t

45 myopathy, Friedreich ataxia, and 3-hydroxy-3-methylglutaryl-CoA lyase deficiency.

46 unction with a partial defect in 3-hydroxy-3-methylglutaryl-CoA lyase, and accumulation of oxidative

47 3-Hydroxy-3-methylglutaryl-CoA lyase-like protein (HMGCLL1) has been

48 normal yeast ER membrane protein 3-hydroxy-3-methylglutaryl-CoA reductase (Hmg2p) undergoes ERAD that

49 ines, SUGP1 knockdown stimulated 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) alternative splicin

50 ecognition protein (SRP) or anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies (Abs), a

51 combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene.

52 udies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called s

53 3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the target of th

54 s a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug

55 nt binding factor 2 (Srebf2) and 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr).

56 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the format

57 The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme catalyzes the

58 ticulum (ER) and the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) imbedded therein res

59 mised proteasomal degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) or deficient in ubiq

60 Hepatic 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) protein and mRNA are

61 eedback-regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR).

62 s of isoprenoids is catalysed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR).

63 by 84% with empagliflozin, while 3-hydroxy-3-methylglutaryl-CoA reductase activity and total choleste

64 ximately 20-fold) decrease in ER 3-hydroxy-3-methylglutaryl-CoA reductase activity in vitro.

65 are associated with decreases in 3-hydroxy-3-methylglutaryl-CoA reductase and increases in ATP-bindin

66 dependent manner and whether the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin can

67 ed the effects of simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, on hippocampal A

68 of isoprenoid synthesis with the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, simvastatin (Sim

69 2 in response to Ang II by using 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors and isoprenoid i

70 The use of statins, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors that block the s

71 cent reports suggest that statins (hydroxy-3-methylglutaryl-CoA reductase inhibitors) exhibit potenti

72 ition, our results indicate that 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, a class of chol

73 ase (squalene synthase), but not 3-hydroxy-3-methylglutaryl-CoA reductase or farnesyl diphosphate syn

74 The endoplasmic reticulum enzyme 3-hydroxy-3-methylglutaryl-CoA reductase produces mevalonate, which

75 ciated degradation of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase represents one mechanism by

76 pharmacologic inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase that are potent regulators

77 farnesyl-pyrophosphate synthase, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotei

78 reatment reduced the activity of 3-hydroxy-3-methylglutaryl-CoA reductase, but it did not change acti

79 doplasmic reticulum (ER) enzyme, 3-hydroxy-3-methylglutaryl-CoA reductase, catalyzes the production o

80 nd -2 increased on promoters for 3-hydroxy-3-methylglutaryl-CoA reductase, fatty-acid synthase, and s

81 ized that statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, inhibit cardiac hypertroph

82 ect is through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase.

83 ive effect, indicating the role of hydroxy-3-methylglutaryl-CoA reductase.

84 in cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase.

85 ect repression of sterol enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 and methylsterol monooxyge

86 Of these 10 genes, the 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (HMGCS2) was the highest u

87 etabolism pathway, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), as a major down-

88 hain acyl-CoA dehydrogenase, and 3-hydroxy-3-methylglutaryl-CoA synthase 2, and enhances fat metaboli

89 of VMH ketone production with a 3-hydroxy-3-methylglutaryl-CoA synthase inhibitor reversed the 3- to

90 Replacement of 3-hydroxy-3-methylglutaryl-CoA synthase's glutamate 95 with alanine

91 o the hydrophobic active site of 3-hydroxy-3-methylglutaryl-CoA synthase, site-directed mutagenesis w

92 synthases, polyketide synthases, 3-hydroxy-3-methylglutaryl-CoA synthases, and biosynthetic thiolases

93 Furthermore, we show that the 3-hydroxy-3-methylglutaryl-CoA-reductase inhibitor mevastatin, which

94 Treatment with the 3-hydroxy-3-methylglutaryl coenyzme A reductase inhibitors (or stati

95 signal recognition particle and 3-hydroxy-3-methylglutaryl-coenzime A reductase (HMG-CoA) reductase.

96 ically active Haloferax volcanii 3-hydroxy-3-methylglutaryl coenzyme A (CoA) synthase (EC 2.3.310).

97 3-Hydroxy-3-methylglutaryl coenzyme A (CoA) synthase (HMGCS) catalyz

98 alcohol dehydrogenase, elongation factor-TU, methylglutaryl coenzyme A (CoA), acyl CoA synthetase, ox

99 pting the H. capsulatum homolog of 3-hydroxy-methylglutaryl coenzyme A (HMG CoA) lyase (HCL1).

100 e possible by the development of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors

101 n-2 receptor blockers, and beta-hydroxy-beta-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors

102 ig-1 also binds to the ER enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, facilitat

103 erol biosynthetic pathway enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.

104 rotein predicted to possess both 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and acetyl

105 o assess the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition

106 patients derive benefit from the 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor

107 the possible effects of a novel 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor,

108 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

109 Although 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

110 Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

111 n randomized, controlled trials, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

112 iotropic activities reported for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

113 Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

114 re, cholesterol-lowering agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

115 left ventricular thrombus; using 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

116 Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

117 ical trials have shown that the 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

118 tensin-receptor blockers (ARBs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors

119 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-

120 the sterol biosynthetic enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase isozyme, H

121 The biodegradative 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase of Pseudom

122 2 cells) that expresses only one 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase protein wh

123 hich encodes a putative class II 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is essent

124 atins, a class of inhibitors for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, significa

125 (NK-104) is a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-

126 n is a specific inhibitor of three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, used comm

127 ed efferocytosis in vitro in an 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase-dependent

128 ysis has revealed two classes of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

129 evels of the ER membrane protein 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase.

130 There are two classes of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase: the class

131 ine 110 of Enterococcus faecalis 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase was mutated

132 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, a key regu

133 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, a member o

134 promoters of the genes encoding 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, farnesyl d

135 ate pyrophosphate decarboxylase, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, HMG-CoA re

136 olate the mvaS gene that encodes 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, the second

137 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A HMG-CoA reductase (statins) ha

138 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) inhibit m

139 s of lipid modification with the 3-hydroxy-3-methylglutaryl coenzyme A inhibitors, or statins.

140 tazone) as well as metformin and 3-hydroxy-3-methylglutaryl coenzyme A inhibitors.

141 at block the rate-limiting step (3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase))

142 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAr) provides a

143 ilisation of cholesterol, in the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) activity, an

144 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors,

145 homocysteine (Hcy) revealed that 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) was upregula

146 mRNA leading to the formation of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a main regu

147 stimulates the ubiquitination of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which catal

148 t histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) by having a h

149 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) has a key reg

150 have demonstrated that statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) inhibitors, a

151 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modula

152 or expression) and biosynthesis (3-hydroxy-3-methylglutaryl coenzyme A reductase activity) are regula

153 Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase and effective lipid-

154 , not only statins targeting the 3-hydroxy-3-methylglutaryl coenzyme A reductase but also inhibitors

155 osynthesis through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase but has no effect on

156 had the catalytic domain of the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene integrated into

157 e effect, confirming the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition and sugge

158 poprotein (LDL) cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ("statin")

159 ge of long-term persistence with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) t

160 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) t

161 vational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) u

162 Simvastatin, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, effective

163 pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been

164 We studied the effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, simvastat

165 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

166 nce is available to suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

167 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

168 Although 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

169 py and when co-administered with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

170 ors, proton-pump inhibitors, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

171 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

172 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

173 Cardiovascular risk reduction by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

174 Hepatic 3-methylglutaryl coenzyme A reductase inhibitors (statins)

175 evention benefit of therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

176 trospective studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

177 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

178 controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

179 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

180 As 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)

181 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors have been

182 The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patien

183 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or "stati

184 We found that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors rapidly a

185 Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are an i

186 Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are asso

187 Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are curr

188 t beneficial effects of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) on renal

189 Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) promote

190 Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), commonl

191 he debate whether statins, 3-hydroxymethyl-3-methylglutaryl coenzyme A reductase inhibitors, are safe

192 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, statins,

193 results indicate that 'statins', 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, which ar

194 synthase kinase-3 inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

195 on upon Insig-1 binding, whereas 3-hydroxy-3-methylglutaryl coenzyme A reductase is ubiquitinated and

196 ciated with a marked increase in 3-hydroxy-3-methylglutaryl coenzyme A reductase protein.

197 3-hydroxy-3-methylglutaryl coenzyme A reductase regulates the produc

198 the first step of this pathway (3-hydroxy-3-methylglutaryl coenzyme A reductase) reduces the growth

199 HMGCR(3-Hydroxy-3-methylglutaryl coenzyme A reductase), the direct target

200 y acid synthase, squalene epoxidase, hydroxy-methylglutaryl coenzyme A reductase), while genes involv

201 l-regulated ubiquitination marks 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-determining

202 n and proteasomal degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-limiting enz

203 rol synthesis-regulating enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and the cholesterol

204 -1 (SREBP-1), fatty acid synthase, hydroxy-3-methylglutaryl coenzyme A reductase, farnesyl pyrophosph

205 Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, have been used succ

206 By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, statins not only re

207 ER) allows for ubiquitination of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting e

208 tatins as dependent on inhibition of hydroxy-methylglutaryl coenzyme A reductase, we treated C57Bl/6

209 body by specifically inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is a rate-lim

210 or the continued proteolysis of 3-hydroxyl-3-methylglutaryl coenzyme A reductase, which may undermine

211 cleavage-activating protein) and 3-hydroxy-3-methylglutaryl coenzyme A reductase.

212 phogen receptor, Patched, and to 3-hydroxy-3-methylglutaryl coenzyme A reductase.

213 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) inhibitors, m

214 duction, proteoglycan synthesis, 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, and cell w

215 yofiber cascades downstream from 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase inhibitio

216 deposition, we hypothesised that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG COA) reductase inhibitors

217 The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase catalyzes the

218 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase catalyzes the

219 rly, apolipoprotein E (ApoE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR)) ha

220 ogenesis, we studied the role of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and alphaP

221 as mediated by inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and subseq

222 Inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase enzyme (st

223 t systemic administration of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor

224 termine the effect of aggressive 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor

225 Until recently, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

226 This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

227 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

228 and smooth muscle cells, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

229 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

230 indings support further study of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors

231 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a criti

232 Mevastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-

233 SNPs were in the gene coding for 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the targe

234 toacetyl-coenzyme A thiolase and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.

235 e signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.

236 Ceestatin binds to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase and irrever

237 ,2-(13)C]acetyl-CoA to wild-type 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase is characte

238 re a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase, a critical

239 ibrios that is distinct from the 3-hydroxy-3-methylglutaryl-coenzyme A pathway seen in pseudomonads.

240 Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase)

241 sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol r

242 Autoantibodies recognizing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are found in

243 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) encodes the

244 mevalonate pathway, such as the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) gene.

245 r alone or in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitor (s

246 ipitation of in vitro-translated 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) protein.

247 al recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).

248 in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target o

249 and time-dependent elevation in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) activity, enh

250 t endoplasmic reticulum protein, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), is regulated

251 eedback-regulated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).

252 Induction of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR; EC 1.1.1.34)

253 we identified a mutation in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 1b (hmgcr1b) gene th

254 Inhibitors of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase and isoprenylation a

255 cleation was also induced by the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin

256 hosphate binding activity by the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastati

257 hown in mice that pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, prevents

258 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins

259 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)

260 Due to the efficacy of 3-hydroxy 3-methylglutaryl-coenzyme A reductase inhibitors (statins)

261 The use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)

262 Purpose The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)

263 The advent of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)

264 The role of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)

265 The 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors, or stati

266 els were noticeably resistant to 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

267 erated degradation of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase is one of several me

268 rs were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti

269 e main synthetic products in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway.

270 cholesterol biosynthetic enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase results from its ste

271 n (SREBP)-1a, SREBP-1c, SREBP-2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylg

272 ns: 1) sterol-induced binding to 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an action that lead

273 element-binding protein 2, human 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and human low-densi

274 iosynthesis rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and increased plasm

275 Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, angiotensin-convert

276 ge-activating protein (SCAP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

277 transactivate the genes encoding 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE1 (HMGR1) and MAKIBIS

278 ylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A synthase, and LDL receptor mRN

279 ation of lipogenic genes such as 3-hydroxy-3-methylglutaryl-coenzyme A synthase, fatty acid synthase,

280 HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR) catalyzes th

281 Statins, or HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, are dru

282 in kinase (SnRK1) phosphorylates 3-hydroxy-3-methylglutaryl-Coenzyme A, nitrate reductase and sucrose

283 several new autoantibodies (e.g. 3-hydroxy-3 methylglutaryl-coenzyme-A reductase and melanoma differe

284 The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors, or stati

285 ignaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in p

286 mponents include a halogenase, a 3-hydroxy-3-methylglutaryl enzyme cassette for polyketide beta-branc

287 uercetin-3-O-hexoside, quercetin 3-hydroxy-3-methylglutaryl-glycoside), an O-triglycosyl flavanone (n

288 4'-methyl ether and scoparin), a 3-hydroxy-3-methylglutaryl glycosyl flavonol (3-hydroxy-3-methylglut

289 ethylglutaryl glycosyl flavonol (3-hydroxy-3-methylglutaryl glycosyl quercetin) and a flavone O-glyco

290 plasmic reticulum (ER)-localized 3-hydroxy-3-methylglutaryl (HMG) CoA reductase.

291 etermine whether atorvastatin, a 3-hydroxy-3-methylglutaryl (HMG)-co-enzyme A (CoA) reductase inhibit

292 Mammalian 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGR) undergoes ster

293 3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGR), the rate-limi

294 The hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin

295 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, e.g., sim

296 reased expression of SREBP-2 and 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, which results in inc

297 iquely among condensing enzymes, 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase (HMGS) catalyzes the f

298 posure to beta-cyclodextrins and 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors (st

299 a gamma-chlorination step on (S)-3-hydroxy-3-methylglutaryl mediated by Cur halogenase, a non-haem Fe

300 The branching enzyme, 3-hydroxy-3-methylglutaryl synthase (HMGS), catalyzes the aldol addi